Cetera Advisor Networks LLC Viking Therapeutics, Inc. Transaction History

Cetera Advisor Networks LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$17.4 - $94.5 $128,411 - $697,410	-7,380 Reduced 31.74%	15,868 $1.3 Million
Q4 2023 Feb 13, 2024	BUY	$9.24 - $19.64 $42,504 - $90,344	4,600 Added 24.67%	23,248 $432,000
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $6,006 - $8,800	550 Added 3.04%	18,648 $206,000
Q2 2023 Aug 09, 2023	BUY	$14.84 - $24.79 $3,264 - $5,453	220 Added 1.23%	18,098 $293,000
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $17,509 - $37,554	2,167 Added 13.79%	17,878 $297,000
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $8,573 - $29,628	3,152 Added 25.1%	15,711 $147,000
Q2 2022 Aug 11, 2022	BUY	$2.11 - $3.15 $26,499 - $39,560	12,559 New	12,559 $36,000

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.